NCT02743611View on ClinicalTrials.gov

Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

April 14, 2017

Primary Completion Date

July 19, 2019

Study Completion Date

July 19, 2020

Conditions
Acute Myeloid LeukemiaMyelodysplastic SyndromeUveal Melanoma
Interventions
BIOLOGICAL

BPX-701

autologous T cells genetically modified to express the αβ TCR reacting with PRAME peptide/HLA-A2.01 (PRAME TCR) and an inducible safety switch

DRUG

Rimiducid

dimerizer infusion to activate the safety switch and induce apoptosis of the BPX-701 T cells in the event of toxicity

Trial Locations (3)

37203

Tennessee Oncology, Nashville

80218

Colorado Blood Cancer Institute, Denver

97239

Oregon Health & Science University, Portland

Sponsors
All Listed Sponsors
lead

Bellicum Pharmaceuticals

INDUSTRY